Sarvajna Dwivedi
About
Detail
CEO, Co-Founder and Board Member
Redwood City, California, United States
Résumé
Jobs
verified_user
0% verified
Strategic External Advisor, Antiviral Drug Discovery (AViDD) CenterStanford University School of MedicineMay 2022 - Jun 2025 (3 years 2 months)Strategic advisor to multiple drug development projects to help prepare the Nation and the world for future global epidemics and pandemics.- CEO, Co-Founder and Board MemberAngioSafe IncNov 2019 - Current (6 years 9 months)Building and growing AngioSafe, Inc. in its quest of solving challenges of complex vascular interventions.
- Chief Scientist, Pharmaceutical Sciences, BioPharmaceuticals R&DAstraZenecaJan 2017 - Oct 2019 (2 years 10 months)Progress early medicines, devices, and new modalities in AstraZeneca-Medimmume-Pearl pipeline. Expand opportunities for current technology platforms. Foster collaboration among scientists in different disciplines and at different locations. Support internal and external commercialization efforts. Support management in its operational and scientific decision-making. Mentor younger generation of scientists.
- RBoard MemberReviva PharmaceuticalsJul 2016 - Apr 2018 (1 year 10 months)Advise and mentor the company founder in financing, operational, and scientific plans. Interface with current and potential future investors to support company's progression.
- Co-Founder, Investor and Board MemberAngioSafe IncJan 2015 - Current (11 years 7 months)Simplifying complex cardiovascular interventions. A series of catheters in development for occlusive arterial diseases.
- Co-Founder and Chief Scientific Officer (2011-2019); EVP, R&D (2007-2011)Pearl Therapeutics IncMay 2007 - Oct 2019 (12 years 6 months)Co-founded Pearl in 2006, and spun it out of Nektar in 2007. 2006-13 Highlights: venture financing of $167.5 million, operational start and establishment of Pearl sites at three US locations, hiring of major functional area leaders, contract product development and manufacturing arrangements, three products advanced to Phase 3 in about 5.5 years, new global IP portfolio prosecution, extensive business development, external communications management, and general management. AstraZeneca acquired Pearl in a $1.15B deal in 2013, substantially expanding pipeline. 2013 Onwards: Commercial production plant designed, built, and approved by several regulatory authorities. Three products launched.
- Director, Product DevelopmentNektar TherapeuticsDec 2002 - Jan 2007 (4 years 2 months)Spun out Pearl Therapeutics, Inc. Responsible for basic pharmaceutical development of partnered and proprietary products. New product planning. IP progression. Business development and general management.
- Director, Delivery Systems DevelopmentAlkermesJun 2000 - Aug 2002 (2 years 3 months)Established a brand new delivery systems department for all AIR technology based products. Partnered device and product development, business development, general management.
- DSenior ManagerDura Pharmaceuticals IncMay 1998 - May 2000 (2 years 1 month)Development of Spiros franchise of products. Drug-device combination development, business development, general management.
- GSenior Scientist; Research InvestigatorGlaxo GlaxoWellcomeOct 1992 - Apr 1998 (5 years 7 months)Development of Advair, Flovent, Serevent, Ventolin. Formulation sciences, manufacturing, particle engineering and device development. Business development and matrixed project leadership.
Education
verified_user
0% verified
- Ph.D., Pharmaceutical Sciences, Pharmaceutical SciencesThe University of British ColumbiaJan 1988 - Dec 1992 (5 years)Conducted award-winning research in the area of powder compaction, discovering a new method of analyzing high speed tablet formation, without the need of complex and expensive simulators.
- MSc, Pharmaceutical Sciences, Pharmaceutical SciencesThe University of British ColumbiaJan 1986 - Dec 1988 (3 years)Advanced training in physical pharmacy. Analyzed the complex system of pharmaceutical grade lactose, and generated evidence to clear up confusion in literature on how various forms of lactose could be incorporated in its solid state.
- M.Pharm., Pharmaceutics, PharmaceuticsIndian Institute of Technology Banaras Hindu University VaranasiJan 1984 - Dec 1986 (3 years)Advanced training in pharmaceutics and pharmacology. Conceived and conducted a Phase 1 study to test a novel formulation for oral absorption enhancement of a poorly soluble drug; demonstrated 200% improvement in bioavailability relative to leading commercial brands.
- M.Pharm, PharmaceuticsIndian Institute of Technology Banaras Hindu University VaranasiJan 1984 - Dec 1986 (3 years)Advanced training in pharmaceutics and pharmacology. Conceived and conducted a Phase 1 study to test a novel formulation for oral absorption enhancement of a poorly soluble drug; demonstrated 200% improvement in bioavailability relative to leading commercial brands.
- B.Pharm. with Honors, Pharmaceutics, PharmaceuticsIndian Institute of Technology Banaras Hindu University VaranasiJan 1980 - Dec 1984 (5 years)Training in industrial and basic pharmacy.
- B.Pharm. with Honors, PharmaceuticsIndian Institute of Technology Banaras Hindu University VaranasiJan 1980 - Dec 1984 (5 years)Training in industrial and basic pharmacy.
- KKendriya Vidyalaya, BHU, VaranasiKendriya Vidyalaya BHU VaranasiJan 1974 - Dec 1980 (7 years)
- Kendriya VidyalayaKendriya VidyalayaJan 1974 - Dec 1980 (7 years)
Awards
verified_user
0% verified
- AlumniUBC Research and Innovation Award (2021)The University of British ColumbiaNov 2021https://alumni.ubc.ca/events/awards/ https://youtu.be/NGPhrn5HgyI
- FAlumni Agent of Change, UBC (2019)Faculty of Pharmaceutical Sciences The University of British Columbia Vancouver BC CanadaMar 2019https://pharmsci.ubc.ca/alumni/agent-of-change Each year, the UBC Faculty of Pharmaceutical Sciences Alumni Agent of Change Award recognizes alumni for remarkable achievements in a clinical, community, education or research field that are having local, national or global impact.
- TNRI of the Year - Entrepreneurship, North America (2018)TIMES NOW and ICICI Bank Mumbai IndiaJul 2018A global series of international awards presented to Non Resident Indians in various disciplines.
- IDistinguished Alumnus, IIT-BHU (2015); Distinguished Alumnus-Research, IIT-BHU (2017)Indian Institute of Technology Banaras Hindu University IndiaJan 2017IIT-BHU selects alumni for distinguished work in their respective fields. IIT-BHU is the only IIT with a pharmaceutical sciences and engineering department, which also was the first ever department of pharmacy in India, established in 1932. It's an honor to be distinguished alumnus of such a premier and legendary department and institute.
- E&Y Entrepreneur of the Year, Finalist, Northern California (2014)Ernst and YoungJun 2014Through the Entrepreneur Of The Year® program, we celebrate the unstoppable entrepreneurs whose unbounded ambitions deliver innovation, growth and prosperity that transform our world.
- TTiE50 Award Winner (three times: 2010, 2012, 2013)TiE Silicon ValleyMay 2013TiE50 is TiE Silicon Valley’s premier annual awards program keenly contested by thousands of early to mid-stage startups worldwide. Participating technology startups benefit from significant exposure to venture capitalists, angels and entrepreneurs; online virtual showcasing, and technology and business partnering/networking. https://sv.tie.org/programs/tie50/
- ASyntax Award, AFPC-Canada (1993)Association of Faculties of Pharmacy of CanadaJul 1993Awarded to one student for excellence in PhD research in Canada.
- AProctor and Gamble Award, AAPS-USA (1991)American Association of Pharmaceutical ScientistsNov 1991Awarded to selected PhD students for novelty, originality and future applicability of their research.